News & Events

Getz Pharma launches Pakistan’s first Metabesity Guideline in collaboration with leading medical societies of the country

As a research-driven pharmaceutical company, Getz Pharma takes an active role in supporting advanced scientific studies that can help patients and healthcare professionals in dealing with life-threatening diseases. This time, Getz Pharma is proud to launch Pakistan’s first Metabesity Guideline in collaboration with leading medical societies of Pakistan.

IBA panel discussion “After COVID: What have we learnt?”

On June 23rd, 2021, the Institute of Business Administration (IBA) held a discussion under their ‘CEO Forum’- a platform where different business leaders gather to present their views on current and impending topics. This time, the topic under discussion was: “After COVID: What have we learnt?”. The panelists at this session included Khalid Mahmood, Managing Director and CEO, Getz Pharma, Dinshaw Avari, Executive Director of Avari Hotels, Huma Adnan, Creative Director of FNKAsia and Craft Stories, Kashan Hasan, CEO Reckitt Pakistan and Azhar Abbas, Managing Director of Geo News. The session was moderated by Akbar Zaidi, Executive Director, IBA Karachi.

Getz Pharma Makes Environmental History

Getz Pharma announced that its new manufacturing facility, named Astola, has been awarded the First LEED Platinum Certification for a pharmaceutical plant in South Asia, by the U.S. Green Building Council.

Getz Pharma And Tabba Heart Institute Partner To Launch A Landmark Study On Cardiovascular Disease

Getz Pharma and Tabba Heart Institute, in order to address the issue of the rising health burden of ASCVD in Pakistan, are entering into a Joint Venture Agreement for the largest, first-of-its-kind, longitudinal cohort study on Atherosclerotic Risk Assessment in Pakistani Population. This study aims to recruit healthy volunteers aged 30 years or older, from selected urban and rural areas of Pakistan, who are asymptomatic and have no cardiovascular disease. This would allow for assessing the participants’ risk factor profiles and follow them up for at least 10 years to document the incidence of ASCVD.